Prosecution Insights
Last updated: November 20, 2026
Application No. 18/262,113

USE OF LINK-TSG6 FOR THE TREATMENT OF OSTEOARTHRITIC PAIN

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Jul 19, 2023
Priority
Jan 20, 2021 — GB 2100761.2 +1 more
Examiner
COFFA, SERGIO
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The University of Manchester
OA Round
3 (Non-Final)
61%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
465 granted / 760 resolved
+1.2% vs TC avg
Strong +32% interview lift
Without
With
+32.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
65 currently pending
Career history
823
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
34.4%
-5.6% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 760 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/8/2026 has been entered. Claim Status Claims 1, 3-5, 13 and 15-17 are pending. Claims 15-17 have been added. Claim 1 has been amended. Claims 1, 3-5, 13 and 15-17 are being examined in this application. Response to Amendment The declaration under 37 CFR 1.132 filed on 9/8/2026 is insufficient to overcome the rejection of claims 1 and 3-5 based upon 35 U.S.C. 102(a)(1) as set forth in the last Office action. Applicant arguments are not persuasive because the claimed unexpected results and long felt need do not apply to a rejection based upon 35 U.S.C. 102(a)(1). Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. This rejection has been modified. Claims 1, 3-5, 13 and 15-17 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims are drawn to a method of treating osteoarthritis pain in a subject comprising administering subcutaneously to the subject a polypeptide comprising a LINK_TSG6, wherein the LINK_TSG6 polypeptide consists of (i) the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 9, or (ii) an amino acid having a sequence at least 90% identity to the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 9 and having the activity of improving weight bearing in a mouse partial medial meniscectomy model as compared to a control treatment; and wherein the treating provides:(1) a reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score as compared to (a) the subject prior to the administering or (b) an untreated control;(2) improved weight bearing as compared to (a) the subject prior to the administering or (b) an untreated control; or (3) a combination of (1) and (2). When referring to the LINK_TSG6, the specification teaches that “[L]INK_TSG6 polypeptide comprises, consists, or consists essentially of (i) the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 9, or (ii) an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 7 or 9” (para [0046]). The specification does not provide any other structural attributes associated with the LINK_TSG6. Without a correlation between structure and function, the claims do little more than define the claimed invention by function. That is not sufficient to satisfy the written description requirement. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406 (“A definition by function alone “does not suffice” to sufficiently describe a coding sequence because it is only an indication of what the gene does, rather than what it is”).” Here, the specification fails to describe what part of the sequence correlates with the required activity (i.e. to treat osteoarthritis pain). The MPEP states that a broad genus can be described by a showing of representative number of examples. The claims in the instant application are broad. Based on the claims, the LINK_TSG6 can be any polypeptide having at least 90% identity to SEQ ID NO: 7 or SEQ ID NO: 9. It is noted that SEQ ID NO: 7 and SEQ ID NO: 9 consist of 92 and 98 amino acids, respectively. Therefore, even considering only naturally occurring amino acids, one would have 6.3x1018 (92x91x90x89x88x87x86x85x84x20) possible polypeptides having at least 90% identity to SEQ ID NO: 7, and 1.14x1019 (98x97x96x95x94x93x92x91x90x20) possible polypeptides having at least 90% identity to SEQ ID NO: 9. However, the specification fails to provide a representative number of examples for the claimed LINK_TSG6. The description requirement of the patent statute requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See In re Wilder, 736 F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming a rejection for lack of written description because the specification does “little more than outline goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate”). Therefore, since the specification fails to identify any relevant structural characteristics that can be attributed to the claimed function and activity, the claimed invention lacks written description. Response to Arguments Applicant’s arguments filed on 9/8/2026 have been fully considered but they are not persuasive. Applicant argues that, as amended, the claims disclose both functional and structural characteristic of LINK_TSG6. Applicant’s arguments are not persuasive. The amendments to claim 1 do not satisfy the written description requirement. “A definition by function alone “does not suffice” to sufficiently describe a coding sequence because it is only an indication of what the gene does, rather than what it is”). See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. Similarly, in the instant case, a definition of a function of the claimed LINK_TSG6 polypeptides without any structural characteristics does not satisfy the written description requirement. Furthermore, as discussed above, the specification exemplifies only SEQ ID NOs: 7 and 9, whereas the claims encompass 6.3x1018 polypeptides having at least 90% identity to SEQ ID NO: 7, and 1.14x1019 polypeptides having at least 90% identity to SEQ ID NO: 9. For the reasons stated above the rejection is maintained. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. This rejection has been modified. Claims 1, 3-5 and 15-17 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Day et al. (US 2015/0057229) as evidenced by Curtis (Osteoarthritis Symptoms and Signs, 11/12/2020) and Milner et al. (A Novel Chondroprotective Property of TSG-6 Has Therapeutic Potential for OA; Osteoarthritis and Cartilage, 24: Abstract, 2 pages (2016)). With respect to claim 1, Day et al. teach a method for inhibiting cartilage degradation in a subject, the method comprising administering to a subject in need of treatment a therapeutically effective amount of a Link_TSG6 polypeptide, or a therapeutically effective amount of a polynucleotide encoding a Link_TSG6 polypeptide, thereby inhibiting cartilage degradation (claim 1), wherein the subject has osteoarthritis (claim 3), and wherein the Link_TSG6 polypeptide comprises, consists or consists essentially of (i) the amino acid sequence of SEQ ID NO: 9, 27, 7 or 26, or (ii) an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 9, 27, 7 or 26 (claim 5). It is noted that SEQ ID NOs: 26 and 27 corresponds to instantly claimed SEQ ID NOs: 7 and 9, respectively. Day et al. also teach that the Link_TSG6 polypeptide is administered subcutaneously (para [0230]). The MPEP 2112.01 states that “'Products of identical chemical composition cannot have mutually exclusive properties.’ A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) (MPEP 2112.01). It is noted that claim 1 requires only the step of administering the Link_TSG6 polypeptide to a subject with osteoarthritis. Therefore, the teachings of Day et al. anticipate the instant claims because, once the Link_TSG6 polypeptide is administered to a subject with osteoarthritis, it would inherently treat osteoarthritic pain. Furthermore, as evidenced by Milner et al. administration of Link_TSG6 polypeptide to subjects with osteoarthritis reduced pain (see “Results”). Similarly, with respect to claims 4 and 15-17, once the Link_TSG6 polypeptide is administered to a subject with osteoarthritis, it would inherently treat referred pain. Alternatively, with respect to claim 4, Day et al. teach that “[O]steoarthritis is a clinical syndrome of joint pain and reduced function of the joint (for example, stiffness and/or reduced range of motion). Symptoms include joint pain, stiffness and problems moving the joint. It may be characterised pathologically by localised loss of cartilage, remodeling of bone and/or inflammation. Joints most commonly affected by arthritis are knee joints, hip joints and joints in the hands and feet, but other joints can also be affected (para [0202]). As evidenced by Curtis, “[W]hile osteoarthritis pain is usually felt in the affected joint, it is possible for the pain to be referred to other areas of the body. For example, hip osteoarthritis may lead to knee pain” (page 2, 3rd para). Therefore, once the Link_TSG6 polypeptide is administered to a subject with hip osteoarthritis, it would inherently treat referred pain. With respect to claims 3 and 5, Day et al. teach that the Link_TSG6 polypeptide is administered weekly (para [0247]). Response to Arguments Applicant’s arguments filed on 9/8/2026 have been fully considered but they are not persuasive. Applicant argues that “[D]ay does not anticipate claims 1 and 3-5 because it does not disclose, expressly or inherently, each and every element of claim 1, as amended, from which claims 3-5 depend. Specifically, Day does not teach a method of treating osteoarthritic pain, and further does not teach that such a method provides a reduction in WOMAC pain score and/or improved weight bearing”. Applicant also argues that “[t]he effect of LINKTSG6 on tactile allodynia described in Milner is attributable to inhibition of local inflammatory processes, suggesting a localised effect in the joint to which the LINKTSG6 polypeptide was administered intra-articularly. This result would not lead to one skilled in the art reasonably expecting that subcutaneous administration of LINKTSG6 would treat OA pain. Instead, it would at best suggest a localised effect in the joint (which in turn impacts peripheral sensitisation in the adjacent paw). The person skilled in the art would therefore consider the results described in Milner to be specific to intra-articular administration and certainly not indicative that a subcutaneously administered LINKTSG6 treatment would result in reduction in WOMAC pain score and/or improved weight bearing”. Applicant’s arguments are not persuasive. The instant claims relate to a method of treating osteoarthritic pain comprising administering subcutaneously a polypeptide comprising LINK_TSG6. The only active step of the claimed method is the subcutaneous administration of a polypeptide comprising LINK_TSG6 to a patient with osteoarthritis (which is characterized by pain). Day et al. clearly teach administering subcutaneously the LINK_TSG6 polypeptide instantly claimed to a patient with osteoarthritis. Therefore, the osteoarthritic pain is inherently treated once the LINK_TSG6 polypeptide is subcutaneously administered to said patient. As previously discussed, this is evidenced by Milner et al., who teaches that administration of LINK_TSG6 polypeptide to patients with osteoarthritis reduced pain. With respect to Applicant’s arguments regarding changing the route of administration from intra-articular to subcutaneous, it is noted that Day et al. anticipates the claims because subcutaneous administration is clearly taught. Thus, there is no need to change the route of administration from intra-articular to subcutaneous. The evidentiary reference of Milner et al. teach that intra-articular administration of the LINK_TSG6 polypeptide provides OA pain relief. Therefore, one of ordinary skill in the art would have reasonably expected both subcutaneous and intra-articular administration to reduce pain in patients with osteoarthritis. For the reasons stated above the rejection is maintained. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This rejection has been modified. Claims 1, 3-5, 13 and 15-17 are rejected under 35 U.S.C. 103 as being unpatentable over Day et al. (US 2015/0057229). The teachings of Day et al. with respect to claims 1, 3-5 and 15-17 have been discussed above. Day et al. do not teach the claimed amount of LINK_TSG6 (i.e. 10 mg to 150 mg). However, Day et al. also teach that “[a] physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0.1 mg/kg to 10 mg/kg of body weight, according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g” (para [0239]). A prima facie case of obviousness necessarily exists when the prior art range overlaps or touches a claimed range, such as in the instant rejection (MPEP § 2144.05). Furthermore, the MPEP 2144.05 A states that “[G]enerally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 (“The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.”); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997)”. Since Applicant has not disclosed that the specific limitations recited in the instant claims are for any particular purpose or solve any stated problem, absent unexpected results, it would have been obvious for one of ordinary skill to discover the optimum workable dosage and time interval between dosages by normal optimization procedures known in the pharmaceutical art. Response to Arguments Applicant’s arguments filed on 9/8/2026 have been fully considered but they are not persuasive. Applicant argues that “[t]he unexpected element of the results is that LINKTSG6 is acting on the CNS and can treat central as well as peripheral pathways of OA pain. For example, as described in Example 3, subcutaneous LINKTSG6 treatment reduces thermal sensitivity (to a cold plate stimulus) for both the ipsilateral (operated leg) and the contralateral (un-operated leg) paw (Figures 3A and 3B). Similarly, subcutaneous LINKTSG6 treatment reduced mechanical sensitivity (to a pressure stimulus) in both the ipsilateral and the contralateral paw (see Examples 4 and Figures 4A and 4B). Professor Day and Dr. Milner further describe the surprising nature of these results at Paragraphs 20-23 of the Declaration. Taken together, these results indicate that LINKTSG6 has effects extending beyond local joint pathology and are consistent with modulation of central pain pathways during OA pain. Without acquiescing to the propriety of the rejection and solely to expedite prosecution, the claims are amended to specify that the method of "treating provides: (1) a reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score as compared to (a) the subject prior to the administering or (b) an untreated control; (2) improved weight bearing as compared to (a) the subject prior to the administering or (b) an untreated control; or (3) a combination of (1) and (2). As set out above, these treatment effects capture a meaningful therapeutic effect on the overall OA pain burden (i.e. including central pain sensitisation mechanisms) rather than merely an effect on local joint pathology. As is further described at Paragraphs 18 and 19 of the Declaration, in view of Milner, which did not demonstrate or suggest contralateral pain reduction effects following intra-articular administration of LinkTSG6, one skilled in the art had no reason to expect that subcutaneous administration would produce a clinically meaningful improvement in such broad measures of OA pain”. Applicant also argues that “[T]here has also been a long-felt need for effective treatments of OA pain. As Professor Day and Dr. Milner describe in Paragraphs 6 and 7 of the Declaration, there is an "enormous and long-felt need for OA pain treatments". Professor Day and Dr. Milner note at Paragraph 7 of the Declaration: Despite decades of research and development work there are still no disease- modifying OA drugs (DMOAD) and existing treatments for OA pain are inadequate. First line options for pain relief include acetaminophen (paracetamol) and non-steroidal anti-inflammatory drugs (NSAID); the latter are COX inhibitors and (even in the case of selective COX-2 inhibitors) are associated with serious gastrointestinal, cardiovascular and renal side effects. This has resulted in several COX-2 inhibitors (e.g. Vioxx) being withdrawn from use. A recent Phase 3 trial (ACTiVION-II) of TG-C (a cell and gene therapy for knee OA, administered by intra-articular injection), which aimed to induce an anti-inflammatory response to both reduce pain and improve cartilage structure, failed to demonstrate statistically significant improvements over placebo in VAS pain and WOMAC function scores at 12 months. NGF (nerve growth factor) inhibitors - e.g. tanezumab and fasinumab - were a promising target for treating OA pain and progressed to Phase 3 trials. However, despite providing good pain relief, these drugs have not been approved by the FDA and development was halted due to adverse events in some patients - most notably, rapidly progressing OA, but also paraesthesia and adverse joint events - even with low dose administration. One skilled in the art would therefore be aware that treating OA pain is challenging and that several OA pain drugs have not progressed past clinical trials, thus contributing to the long- felt need. Accordingly, in view of the results presented in the application and in the Declaration showing that LINKTSG6 can effectively treat OA pain when administered subcutaneously, and especially in view of the present amendments to the claims, Applicant respectfully submits that Claims 1, 3-5, and 13 are not obvious”. Applicant’s arguments are not persuasive. First of all, it is noted that Applicant did not present any argument with respect to the 103 rejection (i.e. the claimed amount of LINK_TSG6). All arguments seem to be related to the 35 U.S.C. 102(a)(1) rejection. However, as discussed above, the claimed unexpected results and long felt need do not apply to a rejection based upon 35 U.S.C. 102(a)(1). Assuming that the claimed unexpected results relate to the claimed amount of LINK_TSG6, it is noted that the MPEP 716.02(d) states that unexpected results must be commensurate in scope with the claimed invention. In the instant case, they are not. Figs. 4A-B and 5A-B show that the administration of a “high” dose of LINK_TSG6 reduced mechanical sensitivity, and improves weight bearing. The specification teaches that a “high” dose is 40 mg/month, which may correspond to approximately 18.2 mg per human per month. First of all, it is noted that the claimed subject encompasses humans as well as other species (which received 40 mg/month). Second, even considering only administration to humans, 18.2 mg per month is not commensurate in scope with the claims, not even if the limitations of claims 5 and 13 were incorporated into claim 1. Furthermore, since Day et al. teach that “[a] physician will be able to determine the required route of administration and dosage for any particular patient”, one of ordinary skill in the art would have arrived at the instantly claimed dose of LINK_TSG6. For the reasons stated above the rejection is maintained. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. This rejection has been modified. Claims 1, 3-5 and 15-17 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 9878003 (hereafter Day et al.), as evidenced by Curtis (Osteoarthritis Symptoms and Signs, 11/12/2020) and Milner et al. (A Novel Chondroprotective Property of TSG-6 Has Therapeutic Potential for OA; Osteoarthritis and Cartilage, 24: Abstract, 2 pages (2016)). Although the claims at issue are not identical, they are not patentably distinct from each other because they relate to the same composition and method instantly claimed. With respect to claim 1, Day et al. teach a method for inhibiting cartilage degradation in a subject, the method comprising administering to a subject in need of treatment a therapeutically effective amount of a Link_TSG6 polypeptide, thereby inhibiting cartilage degradation, wherein the Link_TSG6 polypeptide is a fragment of the human TSG6 polypeptide that consists of (i) the amino acid sequence of SEQ ID NO : 9, 27 , 7 or 26 , or (ii) an amino acid sequence having at least 95 % identity to the amino acid sequence of SEQ ID NO : 9 , 27, 7 or 26 and being capable of inhibiting IL-1a , IL-b or TNFa induced expression of ADAMTS-4 ADAMTS-5 or MMP13 (claim 1), wherein the subject has osteoarthritis (claim 3), and wherein the Link_TSG6 polypeptide comprises, consists or consists essentially of (i) the amino acid sequence of SEQ ID NO: 9, 27, 7 or 26, or (ii) an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 9, 27, 7 or 26 (claim 5). It is noted that SEQ ID NOs: 26 and 27 corresponds to instantly claimed SEQ ID NOs: 7 and 9, respectively. Day et al. also teach that the Link_TSG6 polypeptide is administered subcutaneously (column 27, lines 11-19). Please note that it is proper to turn to and rely on the disclosure of a patent application to ascertain what constitutes an obvious modification. This position is supported by the courts. See In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970). Furthermore, the MPEP 2112.01 states that “'Products of identical chemical composition cannot have mutually exclusive properties.’ A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) (MPEP 2112.01). It is noted that claim 1 requires only the step of administering the Link_TSG6 polypeptide to a subject with osteoarthritis. Therefore, the teachings of Day et al. anticipate the instant claims because, once the Link_TSG6 polypeptide is administered to a subject with osteoarthritis, it would inherently treat osteoarthritic pain. Furthermore, as evidenced by Milner et al. administration of Link_TSG6 polypeptide to subjects with osteoarthritis reduced pain (see “Results”). Similarly, with respect to claims 4 and 15-17, once the Link_TSG6 polypeptide is administered to a subject with osteoarthritis, it would inherently treat referred pain. Alternatively, with respect to claim 4, Day et al. teach that “[O]steoarthritis is a clinical syndrome of joint pain and reduced function of the joint (for example, stiffness and/or reduced range of motion). Symptoms include joint pain, stiffness and problems moving the joint. It may be characterised pathologically by localised loss of cartilage, remodeling of bone and/or inflammation. Joints most commonly affected by arthritis are knee joints, hip joints and joints in the hands and feet, but other joints can also be affected (column 22, lines 46-53). As evidenced by Curtis, “[W]hile osteoarthritis pain is usually felt in the affected joint, it is possible for the pain to be referred to other areas of the body. For example, hip osteoarthritis may lead to knee pain” (page 2, 3rd para). Therefore, once the Link_TSG6 polypeptide is administered to a subject with hip osteoarthritis, it would inherently treat referred pain. With respect to claims 3 and 5, Day et al. teach that the Link_TSG6 polypeptide is administered weekly (column 29, lines 40-48). Response to Arguments Applicant’s arguments filed on 9/8/2026 have been fully considered but they are not persuasive. Applicant arguments have been addressed above under “Response to Arguments” on pages 9-10. For the reasons stated above the rejection is maintained. This rejection has been modified. Claims 1, 3-5, 13 and 15-17 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 9878003 (hereafter Day et al.). The teachings of Day et al. with respect to claims 1, 3-5 and 15-17 have been discussed above. Day et al. do not teach the claimed amount of LINK_TSG6 (i.e. 10 mg to 150 mg). However, Day et al. also teach that “[a] physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0.1 mg/kg to 10 mg/kg of body weight, according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g” (column 28, lines 20-28). A prima facie case of obviousness necessarily exists when the prior art range overlaps or touches a claimed range, such as in the instant rejection (MPEP § 2144.05). Furthermore, the MPEP 2144.05 A states that “[G]enerally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 (“The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.”); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997)”. Since Applicant has not disclosed that the specific limitations recited in the instant claims are for any particular purpose or solve any stated problem, absent unexpected results, it would have been obvious for one of ordinary skill to discover the optimum workable dosage and time interval between dosages by normal optimization procedures known in the pharmaceutical art. Response to Arguments Applicant’s arguments filed on 9/8/2026 have been fully considered but they are not persuasive. Applicant arguments have been addressed above under “Response to Arguments” on pages 13-16. For the reasons stated above the rejection is maintained. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SERGIO COFFA Ph.D./ Primary Examiner Art Unit 1658 /SERGIO COFFA/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Show 1 earlier event
Nov 04, 2024
Response after Non-Final Action
Jan 16, 2026
Non-Final Rejection mailed — §102, §103, §112
Apr 16, 2026
Response Filed
May 06, 2026
Final Rejection mailed — §102, §103, §112
Sep 08, 2026
Response after Non-Final Action
Sep 08, 2026
Request for Continued Examination
Sep 09, 2026
Response after Non-Final Action
Nov 04, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799165
CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS
1y 2m to grant Granted Nov 17, 2026
Patent 12790379
METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASE USING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)
4y 1m to grant Granted Nov 10, 2026
Patent 12790374
METHODS FOR TREATING MYELIN ASSOCIATED DISEASES AND MITOCHONDRIA ASSOCIATED DISEASES
2y 9m to grant Granted Nov 10, 2026
Patent 12780871
POLYPEPTIDES RV3 AND RV4 HAVING ANTI-AGING FUNCTION AND APPLICATIONS THEREOF
4y 7m to grant Granted Nov 03, 2026
Patent 12780877
CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS
1y 1m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
61%
Grant Probability
94%
With Interview (+32.3%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 760 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month